S.A. Mason
VKTX icon

S.A. Mason’s Viking Therapeutics VKTX Stock Holding History

S.A. Mason’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,900
Closed -$113K – 292
2026
Q2 		$113K Buy
+2,900
New +$93.7K 0.03% 269
2026
Q1 		– Sell
-2,900
Closed -$102K – 277
2025
Q4 		$102K Buy
+2,900
New +$103K 0.04% 259
2025
Q3 		– Sell
-1,800
Closed -$47.7K – 357
2025
Q2 		$47.7K Hold
1,800
– – 0.02% 289
2025
Q1 		$43.5K Hold
1,800
– – 0.02% 281
2024
Q4 		$72.4K Buy
1,800
+300
+20% +$17.1K 0.04% 251
2024
Q3 		$95K Sell
1,500
-100
-6% -$5.87K 0.05% 232
2024
Q2 		$84.8K Buy
+1,600
New +$105K 0.05% 226

Other funds holding VKTX

Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

S.A. Mason's VKTX Position: Q3 2026 in Review

S.A. Mason sold out of Viking Therapeutics (VKTX) in Q3 2026, closing a stake of 2,900 shares — an estimated $113K sold.

S.A. Mason first reported a position in VKTX in Q2 2024 and held it in 7 quarters. The position peaked at $113K in Q2 2026. 165 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • S.A. Mason reported no remaining Viking Therapeutics position as of Q3 2026 after selling out during the quarter.
  • S.A. Mason sold 2,900 Viking Therapeutics shares in Q3 2026, an estimated $113K.
  • S.A. Mason first reported a position in Viking Therapeutics in Q2 2024 and held it in 7 quarters.
  • S.A. Mason's Viking Therapeutics position peaked at $113K in Q2 2026.
  • 165 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on S.A. Mason's 13F filing for Q3 2026, filed 13 Oct 2026.